undamentalytics Newsletter
Sign in

Verastem, Inc. cash flow statement

In fiscal 2025, Verastem, Inc.'s operations generated −$138m of cash; it spent $0 on capital projects, leaving free cash flow of −$138m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−75−139−34−54−64−105−138−162
Depreciation and amortisation1010000—
Stock-based pay798867910
Capital spending2000—000
Free cash flow−76−139−34−54—−105−138−162
Free cash flow after stock pay−83−147−42−61—−112−147−172
Shares issued105—10672714197—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: BCYC vs VSTMFDMT vs VSTMPLX vs VSTM

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Verastem, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Verastem, Inc.